Advertisement
APVO vs GNPX
Which Stock Would AI Choose? Aptevo Therapeutics (APVO) vs. Genprex (GNPX) Stock Comparison
Key Takeaways
- Both APVO and GNPX are micro-cap, clinical-stage biotechnology companies with no commercial revenue, making this a comparison of pipeline quality, funding runway, and sentiment rather than profitability.
- APVO (Aptevo Therapeutics) has reported a series of clinical milestones for its lead candidate mipletamig in acute myeloid leukemia (AML, a cancer of the blood and bone marrow), while GNPX (Genprex) has focused on gene therapy and intellectual property expansion across cancer and diabetes programs.
- Relative performance has diverged sharply: both stocks have fallen over the past year, but GNPX has declined more severely than APVO, reflecting weaker market positioning in recent months.
- Tickeron AI Verdict: Based on trend consistency, catalyst momentum, and analyst positioning, Tickeron's AI currently favors APVO over GNPX.
- For more detail, explore APVO Major News, APVO Today's Price Move, GNPX Major News, and GNPX Today's Price Move on their dedicated pages.
- To see how automated strategies are navigating stocks like these, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies that, despite operating in the same broad healthcare sector, pursue different therapeutic approaches and have produced notably different recent market outcomes. APVO, or Aptevo Therapeutics, develops multispecific immuno-oncology candidates designed to help the immune system attack cancer. GNPX, or Genprex, develops gene therapies targeting cancer and diabetes. For traders and investors evaluating speculative biotech names, the contrast between their pipelines, funding positions, and relative performance offers a useful case study in how market positioning and catalysts shape sentiment in the micro-cap space.
APVO Overview and Recent Performance
Aptevo Therapeutics (APVO) is a Seattle-based clinical-stage biotechnology company advancing multispecific antibody candidates built on its ADAPTIR and ADAPTIR-FLEX platforms. Its lead candidate, mipletamig, is being studied in a Phase 1b/2 trial for frontline acute myeloid leukemia (AML). Recent weeks have brought a steady stream of clinical updates: the company reported that ten newly diagnosed AML patients advanced to potentially curative allogeneic stem cell transplant following mipletamig-based treatment, and announced a substantial reduction in infusion-related reactions (IRRs) after refining its protocol. Earlier data showed a 93% clinical benefit rate in a difficult-to-treat, TP53-mutated AML subgroup. Sentiment has also been supported by a "Moderate Buy" analyst consensus and a price target well above the current share price. However, APVO remains pre-revenue with a small market capitalization, and its share price has been highly volatile, having retreated from much higher levels over the trailing year.
GNPX Overview and Recent Performance
Genprex (GNPX) is an Austin-based clinical-stage gene therapy company whose lead oncology candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The company is also advancing GPX-002, a gene therapy candidate for Type 1 and Type 2 diabetes. Recent activity has centered on intellectual property and biomarker research rather than major new efficacy data: GNPX secured patent grants across Japan, Europe, Canada, Australia, and Israel, and presented data identifying TROP2 and PTEN as potential biomarkers for patient selection. The company also announced a collaboration with Roche Diagnostics to validate biomarker assays. Despite these developments, GNPX has experienced a much steeper decline in market value over the trailing year, with its share price down more than 90% year-to-date, underscoring the heavy dilution and sentiment pressures that can affect micro-cap gene therapy names.
Trending AI Robots
For investors who prefer a data-driven approach to names as volatile as these, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of instruments. Because not every bot suits every market environment, only the best-performing and most suitable strategies for current conditions are highlighted in the Trending AI Robots section. This allows traders to compare bots by their historical statistics and approach before deciding which, if any, aligns with their objectives. Explore the Trending AI Robots page to review the current selection and assess how automated systems are positioning across the market.
Head-to-Head Comparison
Although both companies are pre-revenue biotechs, their profiles diverge in meaningful ways. APVO is concentrated in oncology immunotherapy, with a single lead asset generating recurring clinical readouts and a funding arrangement intended to extend its runway. GNPX spans oncology and diabetes gene therapy, a broader but less clinically advanced footprint that has leaned heavily on patent grants and biomarker research in the recent period. On momentum, APVO has maintained analyst coverage and a Buy-leaning consensus, whereas GNPX has contended with deeper share-price erosion and more pronounced dilution concerns. Both carry elevated risk from cash burn, clinical-trial uncertainty, and the possibility of further capital raises, but their relative positioning differs: one is riding a focused stream of clinical catalysts, while the other is building an intellectual property foundation around programs that are earlier in development.
Tickeron AI Verdict
On balance, Tickeron's AI would likely favor APVO in the current environment. The reasoning is probabilistic rather than definitive: APVO has demonstrated more consistent, forward-moving clinical catalysts, retains a supportive analyst consensus, and has exhibited comparatively more resilient market positioning than GNPX, which has faced a steeper decline and heavier dilution pressure. That said, both remain high-risk, speculative micro-caps whose outcomes hinge on clinical results and financing. The verdict reflects a relative preference based on observable trend consistency, catalyst momentum, and stability, not a guarantee of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APVO is a Hold and GNPX is a Hold.
APVO sees MACD Histogram just turned negative
APVO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 41 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (0.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GNPX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for GNPX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 32 similar instances where the indicator exited the overbought zone. In 32 of the 32 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNPX's RSI Oscillator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on GNPX as a result. In 60 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +11.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 150 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (3.498). P/E Ratio (0.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
APVO | GNPX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 95 | 93 | |
P/E GROWTH RATING 1..100 | 97 | 84 | |
SEASONALITY SCORE 1..100 | n/a | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX's Valuation (49) in the Pharmaceuticals Major industry is in the same range as APVO (52) in the Biotechnology industry. This means that GNPX’s stock grew similarly to APVO’s over the last 12 months.
GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as APVO (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to APVO’s over the last 12 months.
GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as APVO (100) in the Biotechnology industry. This means that GNPX’s stock grew similarly to APVO’s over the last 12 months.
GNPX's Price Growth Rating (93) in the Pharmaceuticals Major industry is in the same range as APVO (95) in the Biotechnology industry. This means that GNPX’s stock grew similarly to APVO’s over the last 12 months.
GNPX's P/E Growth Rating (84) in the Pharmaceuticals Major industry is in the same range as APVO (97) in the Biotechnology industry. This means that GNPX’s stock grew similarly to APVO’s over the last 12 months.
| APVO | GNPX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| Stochastic ODDS (%) | N/A | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 90% | N/A |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 76% | 13 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 3 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APVO’s FA Score shows that 0 FA rating(s) are green while GNPX’s FA Score has 0 green FA rating(s).
- APVO’s FA Score: 0 green, 5 red.
- GNPX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APVO’s TA Score shows that 3 TA indicator(s) are bullish while GNPX’s TA Score has 4 bullish TA indicator(s).
- APVO’s TA Score: 3 bullish, 3 bearish.
- GNPX’s TA Score: 4 bullish, 3 bearish.
Price Growth
APVO (@Biotechnology) experienced а -20.59% price change this week, while GNPX (@Biotechnology) price change was -9.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
APVO is expected to report earnings on Nov 12, 2026.
GNPX is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GNPX and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNPX has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNPX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
|---|---|---|---|---|
| GNPX | 100% | +1.46% | ||
| CANF - GNPX | 93% Closely correlated | -1.19% | ||
| APVO - GNPX | 86% Closely correlated | -4.42% | ||
| ICU - GNPX | 82% Closely correlated | -3.06% | ||
| MLEC - GNPX | 76% Closely correlated | N/A | ||
| LONA - GNPX | 76% Closely correlated | -10.07% | ||
More | ||||